CJC-1295 NO DAC / Ipamorelin (5/5mg)

CJC-1295 (No DAC) and Ipamorelin are two complementary synthetic peptides that are often investigated together in molecular and endocrine research. This combination is known to interact with growth hormone signaling pathways, particularly through mechanisms related to natural pulse dynamics and receptor-mediated signaling.

CJC-1295 (No DAC) is a modified growth hormone-releasing hormone (GHRH) analogue, while Ipamorelin is classified as a growth hormone-releasing peptide (GHRP). Together, they are often used as a research stack to study coordinated effects on hormonal signaling, pathway modulation, and cellular communication.

Peptide Combination and Research Synergy

The combination of CJC-1295 (No DAC) and Ipamorelin is often applied in experimental models because of their complementary mechanisms of action.

• CJC-1295 (No DAC) binds to GHRH receptors and supports natural signaling patterns and pulse activation of pathways
• Ipamorelin activates ghrelin receptors (GHS-R) and contributes to regulated signal modulation

In contrast to long-acting variants, the No DAC form is characterized by a shorter duration of action, which makes it relevant for research into physiological pulse patterns and timing-based signal dynamics.

CJC-1295 (No DAC) & Ipamorelin Structure and Molecular Data

CJC-1295 (No DAC)
Peptide Type: GHRH Analog
Molecular Formula: C152H252N44O42
Molecular Weight: ~3367.9 g/mol

Ipamorelin
Peptide Type: GHRP (Growth Hormone-Releasing Peptide)
Molecular Formula: C38H49N9O5
Molecular Weight: ~711.85 g/mol

Both peptides have a different structure and are often used together in biochemical and molecular research to study coordinated receptor interactions and signaling pathways.

CJC-1295 (No DAC) & Ipamorelin Research Findings

This combination has been extensively investigated in endocrine and molecular models with a focus on growth hormone-related signaling and pathway dynamics.

Research shows activity related to:

• Modulation of growth hormone signaling pathways
• Pulse-based receptor activation and signaling dynamics
• Interaction between GHRH and GHS-R receptors
• Coordination of molecular signaling and timing of pathways

Major Research Areas of the Combination

Endocrine Research
Focus on growth hormone signaling, pulse dynamics, and pathway regulation.

Molecular research
Study of receptor interactions, signal timing and modulation of pathways.

Metabolic Research
Analysis of interactions between hormonal signaling and metabolic processes.

Systemic Research
Investigation of coordinated signaling patterns within complex biological systems.

Scientific Relevance of the CJC-1295 (No DAC) & Ipamorelin Stack

The combination of CJC-1295 (No DAC) and Ipamorelin is considered to be an accurate research peptide stack, especially relevant for studies focusing on natural signal rhythms and pulse-based pathway activation.

By activating both GHRH and ghrelin receptor pathways, researchers can study coordinated signaling mechanisms and synchronization of pathways within experimental models.

Due to its short-acting nature, this combination is especially suitable for research that requires timing-sensitive interventions and controlled signaling patterns, which distinguishes it from long-acting peptide variants.

References

Teichman SL. et al. (2006). Effects of GHRH analogs on growth hormone signaling.

Smith RG. et al. (2005). Ghrelin receptor agonists and their role in endocrine signaling.

Veldhuis JD. et al. (2009). Regulation of growth hormone secretion dynamics.